Iktos Raises € 15.5M Series A Round To Expand Its Artificial Intelligence-Based Drug Discovery Technologies And Solutions

Mar 09, 2023•over 2 years ago

Amount Raised

€15.5 Million

Round Type

series a

ParisMachine LearningArtificial IntelligenceBiotechnologyInformation TechnologySoftware

Investors

Omnes CapitalDebiopharm Innovation FundM Ventures

Description

Iktos, a company specializing in artificial intelligence for new drug discovery, today announces the closing of a € 15.5m Series A financing co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital.

Company Information

Company

Iktos

Location

Paris, Texas, United States

About

Iktos is a French start-up specializing in the development of artificial intelligence (AI) solutions applied to chemical research, more specifically to medicinal chemistry and new drug design. Iktos develops a proprietary and innovative solution based on generative deep learning models, which allows, from existing data, to design optimized molecules in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology platform enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as professional services and as a SaaS software platform, MakyaTM. Iktos also develops SpayaTM, a synthesis planning software based on Iktos' proprietary AI technology for retrosynthesis. Iktos has already validated its technology through more than 50 collaborations with pharmaceutical and biotech companies such as Chiesi Group, Galapagos, Janssen, Merck, Teijin, Ono Pharmaceuticals, Pfizer, Servier, UCB...

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech